
The insulin is designed as an alternative to daily basal insulin

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

Construction is expected to be completed in phases from the end of 2027 into 2028

The companies aim to develop next-generation oral medicines for obesity and diabetes

The reduction in price to $675 will take effect at the beginning of next year

The companies are working together on cellular medicines to boost, replace or repair biological functions

Obesity affects approximately 15 million people in the UK

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid